Stalemate breaks on telehealth prescriptions of stimulants and addiction treatment DEA allows one-year extension of flexibility given health providers during pandemic

https://www.statnews.com/2024/11/15/telehealth-prescriptions-adderall-buprenorphine-prescriptions/?utm_campaign=morning_rounds&utm_medium=email&_hsenc=p2ANqtz--uPEKLMXEQV9H4H8-bDT5suFrA_0SWqP8QvuTOFrnkVGik2ARBQta8UvbhuQnhFpDByief_IgjksJJ2jDOLruKRNx51A&_hsmi=334357151&utm_content=334357151&utm_source=hs_email Federal officials have extended pandemic-era rules that allow health providers to prescribe drugs for opioid addiction and ADHD over telehealth. This temporary ruling is the Drug Enforcement Agency’s latest punt, and the extension to the end of 2025 will saddle the incoming Trump Administration with a decision. In 2023, the Drug Enforcement Agency released rules for reinstating restrictions that were criticized by telehealth advocates and providers, and last October it extended the flexibilities to the end of this year. The flexibility allows prescribers to help their patients access treatments such as buprenorphine and Adderall, and has proved a boon to telehealth companies. Read more about the issue from STAT’s Mario Aguilar and Katie Palmer.